Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application DOI Creative Commons

J. Nandhini,

Karthikeyan Elumalai

Chronic Diseases and Translational Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD). Existing treatments, including cholinesterase inhibitors and N‐methyl D‐aspartate (NMDA) receptor antagonists, do not reverse or slow the course but only treat its manifestations. This limitation brought attention need treatments that modify amyloid‐beta (Aβ) tau pathology of disease. One recent advancement in AD is donanemab, a monoclonal antibody intended clear Aβ plaques brain. It targets pyroglutamyl(3)‐Aβ protein (3–42) remove deposits alter course. review explores timeline donanemab use from discovery clinical use. The pharmacodynamics pharmacokinetics drug are discussed along with typical suboptimal preclinical trial results terms efficacy, safety, tolerability. Thus, more effective than donepezil rivastigmine removing improving cognition. At same time, it devoid safety concerns majority amyloid‐targeted medicines. control end after plaque cleaning unique selling point some patients, making attractive. innovation development practice representation role field translational medicine practical application new knowledge AD.

Language: Английский

Curcumin-loaded polymeric nanomaterials as a novel therapeutic strategy for Alzheimer's disease: A comprehensive review DOI
Jinjin Pei, Chella Perumal Palanisamy, Prabhu Manickam Natarajan

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 99, P. 102393 - 102393

Published: June 24, 2024

Language: Английский

Citations

8
Exosomes in Regulating miRNAs for Biomarkers of Neurodegenerative Disorders DOI
Azhagu Madhavan Sivalingam,

Darshitha D Sureshkumar

Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 7, 2025

Language: Английский

Citations

1
An effective strategy based on electrostatic interaction for the simultaneous sequential purification and isolation of exosomes DOI
Haihong Chen,

Miaoxia Ma,

Lingyi Zhang

et al.

Microchimica Acta, Journal Year: 2025, Volume and Issue: 192(4)

Published: March 26, 2025

Language: Английский

Citations

0
Exosome‐Based Vaccines: Pioneering New Frontiers in Combating Infectious Diseases and Cancer DOI
Xuejun Wang, Aixue Li,

Ailing Wang

et al.

Small Methods, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Abstract Exosomes, small extracellular vesicles with lipid bilayer membranes, play a crucial role in cellular communication and can transfer diverse biological cargo, including proteins, lipids, nucleic acids, from donor to recipient cells. Exosomes possess immunological properties, such as antigen delivery immune activation, along excellent drug capabilities, making them promising candidates for vaccine development. For different diseases, exosome‐based vaccines be designed therapeutic or prophylactic by leveraging immunity humoral immunity. With the emergence of precision medicine, personalized demonstrate exceptional potential. This review systematically introduces sources, biogenesis mechanisms, components exosomes describes their regulatory roles system. Subsequently, preparation, administration, therapy are discussed. Finally, applications clinical trials fields anti‐infection anti‐tumor therapies particularly highlighted, an analysis potential challenges future

Language: Английский

Citations

0
Clodronate Reduces ATP-Containing Microvesicle Releasing Induced by Nociceptive Stimuli in Human Keratinocytes DOI Open Access
Filippo Renò, Marco De Andrea, Stefano Raviola

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(15), P. 8435 - 8435

Published: Aug. 2, 2024

Clodronate (Clod), a first-generation bisphosphonate, acts as natural analgesic inhibiting vesicular storage of the nociception mediator ATP by nucleotide transporter (VNUT). Epidermal keratinocytes participate in cutaneous nociception, accumulating within vesicles, which are released following different stimulations. Under stress conditions, produce microvesicles (MVs) shedding from plasma membrane evagination. MV secretion has been identified novel and universal mode intercellular communication between cells. The aim this project was to evaluate if two nociceptive stimuli, Capsaicin Potassium Hydroxide (KOH), could stimulate human keratinocytes, these MVs contain ATP, Clod inhibit phenomenon. In our cellular model, HaCaT keratinocyte monolayer, both KOH stimulated release after 3 h incubation, contained ATP. Moreover, (5 µM) able reduce Caps-induced abolish one induced, while Dansylcadaverine, an endocytosis inhibitor uptake, partially failed block bisphosphonate activity. Based on new data given role activation vehicle for pain, “old” provide pharmacological basis develop local drugs.

Language: Английский

Citations

1
Biomarkers of Synaptic Degeneration in Alzheimer’s Disease DOI
Qian Cheng,

Yiou Fan,

Pengfei Zhang

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: unknown, P. 102642 - 102642

Published: Dec. 1, 2024

Language: Английский

Citations

1
A meta-analysis of age-dependent changes in extracellular vesicle proteins in C. elegans DOI Creative Commons
Prasun Kumar Bhunia, Prasad Kasturi

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 28, 2024

Abstract Extracellular vesicles (EVs) contribute to the maintenance of organism-wide proteostasis by mediating intercellular communication. Loss and altered communication are associated with aging age-related diseases, suggesting key roles for EVs. However, it is unclear how proteome EVs changes age. To identify EV-associated proteins (EVAPs) their fate age, we curated publicly available data from C. elegans model organism. Our analysis reveals that carry involve protein quality control. We found abundance EV significantly Many these also aggregate age overlap Aβ driven aggregates. observe a subset alter in response heat stress pathogen infections Further, human orthologs EVAPs brain tissues affected Alzheimer’s disease. This meta-analysis highlights composition, changes, aggregation during aging, disease conditions. Overall, this study provides new insights into dynamics may possibly help identifying potential biomarkers diseases.

Language: Английский

Citations

0
Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application DOI Creative Commons

J. Nandhini,

Karthikeyan Elumalai

Chronic Diseases and Translational Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD). Existing treatments, including cholinesterase inhibitors and N‐methyl D‐aspartate (NMDA) receptor antagonists, do not reverse or slow the course but only treat its manifestations. This limitation brought attention need treatments that modify amyloid‐beta (Aβ) tau pathology of disease. One recent advancement in AD is donanemab, a monoclonal antibody intended clear Aβ plaques brain. It targets pyroglutamyl(3)‐Aβ protein (3–42) remove deposits alter course. review explores timeline donanemab use from discovery clinical use. The pharmacodynamics pharmacokinetics drug are discussed along with typical suboptimal preclinical trial results terms efficacy, safety, tolerability. Thus, more effective than donepezil rivastigmine removing improving cognition. At same time, it devoid safety concerns majority amyloid‐targeted medicines. control end after plaque cleaning unique selling point some patients, making attractive. innovation development practice representation role field translational medicine practical application new knowledge AD.

Language: Английский

Citations

0